Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).
Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U, Nolte F, Götze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U.
Schuler E, et al. Among authors: bacher u.
Leukemia. 2016 Jul;30(7):1580-2. doi: 10.1038/leu.2015.340. Epub 2015 Dec 15.
Leukemia. 2016.
PMID: 26668126
Clinical Trial.
No abstract available.